Roche Hldg Ltd Spons (RHHBY) 36.3400 $RHHBY
PDL BioPharma Sees Higher-than-Expected Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 51 mins ago
PDL BioPharma (PDLI) announced that it expects to generate revenues of roughly $165 million in the third quarter of 2014.
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
Roche's (RHHBY) RoActemra Gets EU Approval for Early RA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:20PM CDT
Positive news flowed in at Roche (RHHBY) when its RA drug RoActemra received approval from the European Commission to treat patients suffering from early RA who have previously not been treated with methotrexate (MTX).
Two Promising Gene Therapy Stocks Tackling Eye Disease
at The Street - Tue Sep 09, 8:04AM CDT
Investors will get a first look at data from an early stage study of an Applied Genetic therapy on Friday.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
The Surprising 7 States Where Melanoma Most Often Occurs
Sean Williams, The Motley Fool - Motley Fool - Sun Sep 07, 10:52AM CDT
Source: National Cancer Institute via Wikimedia Commons. Cancer is a scary disease regardless of its type, but for those suffering with melanoma, a malignant form of skin cancer, it's been an especially frightening couple of decades. According to...
Merck's Anti-PD-1 Drug Keytruda First to be Launched in US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 10:20AM CDT
The FDA approved Merck & Co.'s (MRK) advanced melanoma treatment, Keytruda.
Merck PD-1 Inhibitor Approved For Skin Cancer
at Investor's Business Daily - Thu Sep 04, 3:33PM CDT
Merck's (MRK) pembrolizumab won FDA approval for melanoma Thursday afternoon, making it the first drug in the much-anticipated PD-1 inhibitor class to hit the U.S. market. Pembrolizumab, now branded Keytruda, was approved before the normal three...
Biotech Advancements in Innovative Cancer Therapy Reveal Developing Systemic Treatment Options - Company Receives Recommendation from World Health Organization for Lead Drug Candidate
PR Newswire - Thu Sep 04, 7:15AM CDT
Biotech companies seeking to make progress with Hepatocellular Carcinoma (HCC) therapies and other cancer therapeutics: GenSpera Inc. (OTC: GNSZ), Roche Holding AG (OTC: RHHBY), Eli Lilly and Company (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Johnson and Johnson (NYSE: JNJ) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI)
Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:55PM CDT
Roche (RHHBY) announced that its cobas 6800/8800 systems -- two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.
Infinity, AbbVie team on drug
at Investor's Business Daily - Wed Sep 03, 5:36PM CDT
Small biotech Infinity Pharmaceuticals (INFI) agreed to develop its blood cancer drug duvelisib, currently in trial stage, with big pharma AbbVie (ABBV). The deal includes an upfront payment of $275 mil to Infinity, and up to $530 mil in milestone...
INTERMUNE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Against InterMune, Inc. in Connection With Sale of Company to Roche Holding AG -- ITMN
GlobeNewswire - Wed Sep 03, 4:40PM CDT
The Law Offices of Vincent Wong notifies investors of claims of breaches of fiduciary duty against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune"
in connection with the sale of the Company to Roche Holding AG. A complaint was filed in California state court.
Infinity Pharma Joins AbbVie On Blood Cancer Drug
at Investor's Business Daily - Wed Sep 03, 12:20PM CDT
Development-stage biotech Infinity Pharmaceuticals (INFI) landed a key deal to develop its blood cancer drug duvelisib in partnership with big pharma AbbVie (ABBV), sending Infinity stock up 46% to a six-month high near 16 on the stock market today....
Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 9:40AM CDT
Exelixis (EXEL) shares nosedived over 55% on Sep 2 following the announcement that cabozantinib failed to meet the primary endpoint in a phse III study.
Why Exelixis Inc. Stock Plunged
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:53PM CDT
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service. We hope you enjoy this complimentary peek! What: Shares of Exelixis , a biopharmaceutical company focused on developing...
Is It Time to Buy Johnson & Johnson's Stock?
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:36PM CDT
A common belief among investors is that it can be considerably tougher for megacap blue-chip companies to double compared to small-caps stocks. Healthcare conglomerate Johnson & Johnson would like to put to rest those assumptions based on its...
Exelixis Drug Fails Pivotal Prostate Cancer Study
at The Street - Tue Sep 02, 8:33AM CDT
As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce.
Exelixis, Inc.'s Not So Excellent Prostate Cancer Trial Results
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 6:15AM CDT
"I was wrong." Next to "Yes, I'll do the dishes" there may not be a rarer phrase to come out of my mouth. But, today it's the truth with Exelixis ' phase 3 COMET-1 trial involving cabozantinib (known commercially as Cometriq) going up in smoke. ...
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
PDL BioPharma Sees Higher-than-Expected Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 51 mins ago
PDL BioPharma (PDLI) announced that it expects to generate revenues of roughly $165 million in the third quarter of 2014.
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
Roche's (RHHBY) RoActemra Gets EU Approval for Early RA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:20PM CDT
Positive news flowed in at Roche (RHHBY) when its RA drug RoActemra received approval from the European Commission to treat patients suffering from early RA who have previously not been treated with methotrexate (MTX).
Two Promising Gene Therapy Stocks Tackling Eye Disease
at The Street - Tue Sep 09, 8:04AM CDT
Investors will get a first look at data from an early stage study of an Applied Genetic therapy on Friday.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
The Surprising 7 States Where Melanoma Most Often Occurs
Sean Williams, The Motley Fool - Motley Fool - Sun Sep 07, 10:52AM CDT
Source: National Cancer Institute via Wikimedia Commons. Cancer is a scary disease regardless of its type, but for those suffering with melanoma, a malignant form of skin cancer, it's been an especially frightening couple of decades. According to...
Merck's Anti-PD-1 Drug Keytruda First to be Launched in US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 10:20AM CDT
The FDA approved Merck & Co.'s (MRK) advanced melanoma treatment, Keytruda.
Merck PD-1 Inhibitor Approved For Skin Cancer
at Investor's Business Daily - Thu Sep 04, 3:33PM CDT
Merck's (MRK) pembrolizumab won FDA approval for melanoma Thursday afternoon, making it the first drug in the much-anticipated PD-1 inhibitor class to hit the U.S. market. Pembrolizumab, now branded Keytruda, was approved before the normal three...
Biotech Advancements in Innovative Cancer Therapy Reveal Developing Systemic Treatment Options - Company Receives Recommendation from World Health Organization for Lead Drug Candidate
PR Newswire - Thu Sep 04, 7:15AM CDT
Biotech companies seeking to make progress with Hepatocellular Carcinoma (HCC) therapies and other cancer therapeutics: GenSpera Inc. (OTC: GNSZ), Roche Holding AG (OTC: RHHBY), Eli Lilly and Company (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Johnson and Johnson (NYSE: JNJ) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI)
Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:55PM CDT
Roche (RHHBY) announced that its cobas 6800/8800 systems -- two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.
Infinity, AbbVie team on drug
at Investor's Business Daily - Wed Sep 03, 5:36PM CDT
Small biotech Infinity Pharmaceuticals (INFI) agreed to develop its blood cancer drug duvelisib, currently in trial stage, with big pharma AbbVie (ABBV). The deal includes an upfront payment of $275 mil to Infinity, and up to $530 mil in milestone...
INTERMUNE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Against InterMune, Inc. in Connection With Sale of Company to Roche Holding AG -- ITMN
GlobeNewswire - Wed Sep 03, 4:40PM CDT
The Law Offices of Vincent Wong notifies investors of claims of breaches of fiduciary duty against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune"
in connection with the sale of the Company to Roche Holding AG. A complaint was filed in California state court. Infinity Pharma Joins AbbVie On Blood Cancer Drug
at Investor's Business Daily - Wed Sep 03, 12:20PM CDT
Development-stage biotech Infinity Pharmaceuticals (INFI) landed a key deal to develop its blood cancer drug duvelisib in partnership with big pharma AbbVie (ABBV), sending Infinity stock up 46% to a six-month high near 16 on the stock market today....
Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 9:40AM CDT
Exelixis (EXEL) shares nosedived over 55% on Sep 2 following the announcement that cabozantinib failed to meet the primary endpoint in a phse III study.
Why Exelixis Inc. Stock Plunged
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:53PM CDT
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service. We hope you enjoy this complimentary peek! What: Shares of Exelixis , a biopharmaceutical company focused on developing...
Is It Time to Buy Johnson & Johnson's Stock?
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:36PM CDT
A common belief among investors is that it can be considerably tougher for megacap blue-chip companies to double compared to small-caps stocks. Healthcare conglomerate Johnson & Johnson would like to put to rest those assumptions based on its...
Exelixis Drug Fails Pivotal Prostate Cancer Study
at The Street - Tue Sep 02, 8:33AM CDT
As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce.
Exelixis, Inc.'s Not So Excellent Prostate Cancer Trial Results
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 6:15AM CDT
"I was wrong." Next to "Yes, I'll do the dishes" there may not be a rarer phrase to come out of my mouth. But, today it's the truth with Exelixis ' phase 3 COMET-1 trial involving cabozantinib (known commercially as Cometriq) going up in smoke. ...
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
